Skip to main content
OpenTrials
Completed

NCT Number: NCT03298607

The Impact of Serelys PMS on Symptoms of PMS

The objective of the present study is to better define and evaluate Serelys PMS in terms of the impact on the different premenstrual syndrome (PMS) symptoms , tolerance, satisfaction and overall quality of life of women with known discomforts during the premenstrual period. The data from this study will be compared to data when the two different ingredients are given as monotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Department of Nutrition, Exercise and Sports, University of Copenhagen

Copenhagen, 1958FC, Denmark

About this study

More than every other women aged 15 to 50 years of age have premenstrual symptoms such as irritability, mood swings, fatigue, headaches, sleep disturbances, breast and abdominal pain, bloating, water retention and weight gain. Some signs continue during menstruation. These psychological and physical manifestations can make women vulnerable and have a negative impact on their professional, social and sexual life. Randomized, double-blind, placebo-controlled clinical studies demonstrated the beneficial effects of pollen extract in premenstrual discomfort. The premenstrual period is probably caused by a change in the normal amount of sex hormones which can induce disorders in the central neuroendocrine system and estrogens are reported to reduce PMS symptoms to some extend. Moreover, it is well established that serotonin may play a role in PMS, as some inhibitors of serotonin re-uptake (SSRI) have an impact on premenstrual disorders. However, side effects may occur even when using estrogens as well as SSRI. Recently the pollen extract formulation has been improved by adding a natural extract of saffron. This latter component is known for its beneficial action on maintaining comfort during the menstrual cycle of the woman and it especially supports mood changes, one of the mayor PMS symptoms. The effect of Safran was studied more specifically in a randomized controlled double-blind, placebo-controlled clinical trial in women with premenstrual discomfort. This study showed a progressive and significant improvement after the use of saffron. In an other study saffron was documented to improve mood in patients with milder depression.

In summary, the components of saffron helps to improve the well-being of women during the premenstrual and menstrual period and have a well documented impact on mood. The pollen based extracts have well documented impact on most of PMS symptoms but possibly lesser on mood changes, which is also one of the mayor symptoms of PMS. The mechanisms by which saffron and pollen based extraction works is expected to be different and an additive impact is expected. The investigation is initiated by the researchers who feel that in PMS an alternatives to SSRI and estrogen treatment is needed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least five inconveniences in the premenstrual period and which disappear quickly with the end of menstruation : Irritability, Tension, Fatigue, Dysphoria (sadness), Reduced motor coordination, Difficulty concentrating, Changes in libido, Changes in appetite.
  • these inconveniences disappear quickly with the end of menstruation
  • At least one of these criteria must be present in the premenstrual and menstrual period:
  • Deterioration in relations with the family, at home, in school or at work
  • Having thought to take painkillers for at least one menstrual cycle.
  • Have symptoms of dysphoria / premenstrual sadness at least during the previous 6 cycles.

Exclusion criteria

  • Known allergy to any component of the product and known renal and hepatic impairment.
  • Existence of major evolving pathologies
  • Convulsions. Existence of psychiatric disorders, cravings
  • Suicidal thoughts
  • Taking medications that may interfere with PMS symptoms like eg estrogens.
  • Participation in another clinical study at the same time.
  • Pregnancy and / or lactation;
  • Difficulties to collaborate and difficulties to understand and complete the questionnaires.

Treatment and study plan

Placebo

Dietary Supplement

2 months treatment

Serelys PMS

Dietary Supplement

2 months treatment

Primary outcomes

  1. PMS symptoms evaluation - Premenstrual Tension

    Time frame: 2 months

    Premenstrual Tension Scale (PMTS) - Self-rating scale

  2. PMS symptoms evaluation - Premenstrual Tension 2

    Time frame: 2 months

    Premenstrual Tension Scale (PMTS) - Observe Rating Scale

  3. PMS symptoms evaluation - premenstrual discomfort

    Time frame: 2 months

    Evaluation of premenstrual discomfort by Visual Analog Scales (VAS)

Secondary outcomes

  1. Side effect registration

    Time frame: 2 months

    Tolerance will be assessed through a scoring system

  2. Satisfaction scored by the patients

    Time frame: 2 months

    Satisfaction and well-being will be assessed through a scoring system

Sponsors and collaborators

Lead sponsor

Jens Rikardt Andersen

Other

Collaborators

  • Serelys Pharma

Registry information

Official study title

The Impact of Sérélys PMS, a Herbal Remedy Based on Pollen Extraction and Saffron, on Symptoms of PMS: A Randomized, Double-blinded, Placebo Controlled Study

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Oct 2, 2017
Registry last updated
Oct 15, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.